The few published clinical trials that used the GMI as a criterion of activity reported a rather low correlation of the paired time to progression
. However, in some of them, such a low correlation may be due to the heterogeneity of the first-line treatment (different nature of chemotherapy) or to the localization of the tumor.
This study investigated the influence of MMP2, MMP9, and MMP14 gene polymorphisms on time to progression
and overall survival in mesothelioma patients.
The median time to progression
was 2.8 months in the sorafenib group vs.
As expected, the time to progression
was fastest for D1 and slowest for D3.
Future studies are needed to determine whether the biological differences between this type of dysplasia and LGD (eg, longer time to progression
) are sufficient to warrant keeping them as separate entities.
Herbst said: "Obviously, our ultimate goal is to always improve survival for our patients, however the improved time to progression
with less of a number of significant effects is important.
In a prospective trial of nearly 200 patients with metastatic breast cancer, 19 greater numbers of CTCs, measured via Cellsearch, were independently found to be unfavorable and associated with a shorter mean time to progression
and a shorter mean overall survival.
Patients receiving KRX-0401 showed a greater than 60% improvement in overall survival and also demonstrated statistically significant advantage for time to progression
, the company said.
The primary end point was overall survival (OS); secondary end points included overall response rate (ORR), progression-free survival, time to progression
, duration of response, and safety.
In addition to the well-established capecitabine-docetaxel combination treatment mentioned previously, capecitabine plus trastuzumab or capecitabine plus trastuzumab and docetaxel significantly improved time to progression
in two studies.
In combination with chemotherapy drugs synergistic and additive effects have been shown to improve the response rate, time to progression
and survival time.
Median time to progression
(TTP) was estimated to be nine months, which did not appear to differ regardless of RIT dose.